Skip to main content
Premium Trial:

Request an Annual Quote

New York State Grants Clinical Lab Permit to Empire Genomics

NEW YORK (GenomeWeb) – Cancer diagnostics company Empire Genomics announced today that it has received approval from New York State to offer molecular and cellular tumor marker testing through the state's Clinical Laboratory Evaluation Program (CLEP).

The company plans to offer genetic testing and molecular diagnostics to help physicians make treatment decisions for cancer patients. The CLEP program evaluates a clinical lab's ability to accurately and reliably deliver test results.

"The addition of molecular testing solidifies our test menu, allowing us to offer a more complete range of testing needed for personalized diagnostics and therapeutics," said COO John Rushton in a statement.

In December, the firm reported receiving CE Marking for several of its products including fluorescent in situ hybridization probes and karyotyping media.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.